Literature DB >> 6976234

Antibodies against poliomyelitis and measles viruses in immunized and unimmunized children, Ghana 1976-78.

M Böttiger, S Litvinov, F Assaad, H Lundbeck, L Heller, E G Beausoleil.   

Abstract

The serological response of children to two doses of live oral poliomyelitis vaccine (the first at age 3-8 months and the second at age 9-14 months) and to one dose of measles vaccine (at age 9-14 months) was determined in two regions of Ghana. The seroconversion rates after two doses of poliomyelitis vaccine were lower than expected-24% for poliovirus type 1, 60% for type 2, and 52% for type 3; 23% of the subjects were triple negative. A third dose of the vaccine increased the seroconversion rates to 36%, 73%, and 61% for poliovirus types 1, 2, and 3, respectively; the rate for triple negatives fell to 8%. In the course of the study it was found that there was an intensive circulation of wild polioviruses and that a high proportion of 3-8 month-old infants had maternal antibodies.The seroconversion rate following one dose of measles vaccine was about 90%, a response similar to that obtained in temperate climates. The two main conclusions drawn from the study were: (1) two doses of poliomyelitis vaccine are inadequate to provide protection against poliomyelitis in developing countries; and (2) in developing countries measles vaccine should be given as soon as possible after the age of 8 months.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6976234      PMCID: PMC2396115     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  11 in total

1.  Hemagglutination by measles virus. 4. A simple procedure for production of high potency antigen for hemagglutination-inhibition (HI) tests.

Authors:  E NORRBY
Journal:  Proc Soc Exp Biol Med       Date:  1962-12

2.  Antibody response of infants in tropics to five doses of oral polio vaccine.

Authors:  T J John
Journal:  Br Med J       Date:  1976-04-03

3.  The immunological response of Nigerian infants to attenuated and inactivated poliovaccines.

Authors:  S O Oduntan; A O Lucas; E M Wennen
Journal:  Ann Trop Med Parasitol       Date:  1978-04

4.  The Chilean experience with antipoliomyelitis vaccination.

Authors:  J M Borgoño; G Corey
Journal:  Dev Biol Stand       Date:  1978

5.  Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference.

Authors:  T J John; P Jayabal
Journal:  Am J Epidemiol       Date:  1972-10       Impact factor: 4.897

6.  The immune response to vaccination with inactivated poliovirus vaccine in Sweden.

Authors:  M Böttiger; L Arro; H Lundbeck; C R Salenstedt
Journal:  Acta Pathol Microbiol Scand       Date:  1966

7.  Oral polio vaccination of children in the tropics. III. Intercurrent enterovirus infections, vaccine virus take and antibody response.

Authors:  T J John; S Christopher
Journal:  Am J Epidemiol       Date:  1975-11       Impact factor: 4.897

8.  Poliomyelitis survey in Middle-East countries.

Authors:  M Brigaud; M Aymard; D Thouvenot; J J Chomel; R A Mahmood; P P Mathew; A K Jafar
Journal:  Dev Biol Stand       Date:  1978

9.  Paralytic poliomyelitis in the Gaza Strip and West Bank during recent years.

Authors:  C B Gerichter; E E Lasch; I Sever; M el-Massri; P Skalska
Journal:  Dev Biol Stand       Date:  1978

10.  Vaccination with the CHAT strain of type 1 attenuated poliomyelitis virus in Leopoldville. Belgian Congo. 2. Studies of the safety and efficacy of vaccination.

Authors:  S A PLOTKIN; A LEBRUN; H KOPROWSKI
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

View more
  2 in total

1.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

2.  Oral poliovirus vaccine in tropical Africa: greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates.

Authors:  D L Heymann; K Murphy; M Brigaud; M Aymard; A Tembon; G K Maben
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.